Company: ARWR
Filing Date: 2025-03-07
Form Type: 424B7
Source: 0001193125-25-049889
Chunk: 10

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-03-07
Form: 424B7
Chunk 10
---
holder will pay all
underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. We will indemnify the Selling Stockholder against certain liabilities, including some liabilities under the Securities Act, in accordance with the
Investor Rights Agreement, or the Selling Stockholder will be entitled to contribution. We may be indemnified by the Selling Stockholder against civil liabilities, including liabilities under the Securities Act, that may arise from any written
information furnished to us by the Selling Stockholder specifically for use in this prospectus supplement, in accordance with the Investor Rights Agreements, or we may be entitled to contribution.

S-10

LEGAL MATTERS

Certain legal matters relating to the issuance of the Shares offered by this prospectus supplement will be passed upon for us by Gibson, Dunn &
Crutcher LLP, San Francisco, California.

EXPERTS

The consolidated financial statements of Arrowhead Pharmaceuticals, Inc. as of September 30, 2024, and for the year then ended September 30, 2024,
and management’s assessment of the effectiveness of internal control over financial reporting as of September 30, 2024 have been incorporated by reference herein and in the registration statement in reliance upon the reports of KPMG LLP,
independent registered public accounting firm, appearing elsewhere incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.

The financial statements of the Company as of September 30, 2023 and for the two-year period ended
September 30, 2023 incorporated in this prospectus supplement by reference have been audited by Rose, Snyder & Jacobs, LLP as stated in their report incorporated by reference in this prospectus supplement and elsewhere in this
registration statement, and given upon the authority of said firm as experts in auditing and accounting.

S-11

WHERE YOU CAN FIND MORE INFORMATION

We must comply with the informational requirements of the Exchange Act, and we are required to file reports and proxy statements and other information with
the SEC. This prospectus supplement, which forms a part of the registration statement, does not contain all of the information included in the registration statement, including its exhibits and schedules. For further information about us and the
securities described in this prospectus supplement, you should refer to the registration statement, its exhibits and schedules and our reports, proxies, information statements and other information filed with the SEC. Our filings are available to
the public on the Internet, through a database maintained by the SEC at http://www.sec